Cosentyx Half-Life
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis and other conditions, has an apparent half-life of 22 to 31 days in adults with plaque psoriasis after subcutaneous dosing.[1][2]
How Half-Life Varies by Dose and Patient Group
Half-life shortens at higher doses: 27 days at 150 mg, 25 days at 300 mg weekly. In patients with psoriatic arthritis, it's around 22 days. Pediatric data (ages 6+) shows similar ranges, about 28 days.[1][2]
What Affects Elimination
Secukinumab follows nonlinear pharmacokinetics due to target-mediated clearance. Body weight influences exposure inversely—heavier patients clear it faster. No major impact from age, gender, or mild renal impairment; data limited for severe kidney/liver issues.[1]
Dosing Implications
Monthly subcutaneous dosing aligns with the long half-life, maintaining steady-state levels. Steady state reaches in 12 weeks.[1][2]
Comparison to Similar Drugs
| Drug | Half-Life | Target |
|------|-----------|--------|
| Cosentyx (secukinumab) | 22-31 days | IL-17A |
| Taltz (ixekizumab) | 13 days | IL-17A |
| Tremfya (guselkumab) | 15-28 days | IL-23 |
Shorter half-lives mean more frequent dosing for some competitors.[1][3]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: Drugs.com Pharmacokinetics Comparison